(Q36924944)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Neil Barnes

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Andrew Menzies-Gow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Adel H Mansur

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

David Spencer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Fran Percival

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Amr Radwan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

14 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

529-536

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study

28 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Italian real-life experience of omalizumab.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Adverse effects of oral corticosteroids in relation to dose in patients with lung disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Systemic steroids in chronic severe asthma.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3681088

The role of surfactant protein A in bleomycin-induced acute lung injury

4 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F02770903.2013.790419

Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F02770903.2013.790419

Omalizumab for asthma: pharmacology and clinical profile

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23574000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Development of the asthma control test: a survey for assessing asthma control

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23574000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23574000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3109/02770903.2013.790419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

PubMed publication ID

23574000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23574000%20AND%20SRC:MED&resulttype=core&format=json